Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 2
1986 1
1988 3
1989 5
1990 2
1991 5
1992 5
1993 7
1994 20
1995 12
1996 33
1997 45
1998 34
1999 50
2000 59
2001 50
2002 62
2003 46
2004 64
2005 62
2006 65
2007 78
2008 67
2009 65
2010 77
2011 83
2012 97
2013 92
2014 92
2015 105
2016 103
2017 116
2018 113
2019 98
2020 104
2021 82
2022 99
2023 123
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

2,018 results

Results by year

Filters applied: . Clear all
Page 1
Riluzole.
[No authors listed] [No authors listed] 2020 Sep 21. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2020 Sep 21. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000005 Free Books & Documents. Review.
Limited information indicates that maternal doses of riluzole up to 100 mg daily produce low levels in milk and would not be expected to cause any adverse effects in breastfed infants, especially if the infant is older than 2 months. Until more data are available, use r …
Limited information indicates that maternal doses of riluzole up to 100 mg daily produce low levels in milk and would not be expected …
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Jaiswal MK. Jaiswal MK. Med Res Rev. 2019 Mar;39(2):733-748. doi: 10.1002/med.21528. Epub 2018 Aug 12. Med Res Rev. 2019. PMID: 30101496 Review.
Over the past decades, a multitude of experimental drugs have been shown to delay disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but failed to show efficacy in human clinical trials or are still waiting for approval under Phase I-III trial …
Over the past decades, a multitude of experimental drugs have been shown to delay disease progression in preclinical animal models of amyotr …
Motoneuron Disease: Clinical.
Ilieva H, Maragakis NJ. Ilieva H, et al. Adv Neurobiol. 2017;15:191-210. doi: 10.1007/978-3-319-57193-5_7. Adv Neurobiol. 2017. PMID: 28674982 Review.
Riluzole.
Wokke J. Wokke J. Lancet. 1996 Sep 21;348(9030):795-9. doi: 10.1016/S0140-6736(96)03181-9. Lancet. 1996. PMID: 8813989 Review. No abstract available.
Riluzole.
Barnes S. Barnes S. Lancet. 1996 Dec 14;348(9042):1660; author reply 1660-1. doi: 10.1016/S0140-6736(05)65725-X. Lancet. 1996. PMID: 8962007 No abstract available.
Riluzole.
Reynolds DJ. Reynolds DJ. Lancet. 1996 Dec 14;348(9042):1661. doi: 10.1016/s0140-6736(05)65727-3. Lancet. 1996. PMID: 8962008 No abstract available.
Optimizing pharmacologic treatment for ALS to improve outcomes and quality of life.
Lynch K. Lynch K. Am J Manag Care. 2023 Jun;29(7 Suppl):S112-S119. doi: 10.37765/ajmc.2023.89389. Am J Manag Care. 2023. PMID: 37433092 Free article.
Just 3 disease-modifying treatments-edaravone, riluzole, and sodium phenylbutyrate and taurursodiol (PB/TURSO)-are currently FDA approved to slow progression of amyotrophic lateral sclerosis (ALS). ...
Just 3 disease-modifying treatments-edaravone, riluzole, and sodium phenylbutyrate and taurursodiol (PB/TURSO)-are currently FDA appr …
Effects of riluzole on psychiatric disorders with anxiety or fear as primary symptoms: A systematic review.
Kawashima Y, Yamada M, Furuie H, Kuniishi H, Akagi K, Kawashima T, Noda T, Yamada M. Kawashima Y, et al. Neuropsychopharmacol Rep. 2023 Sep;43(3):320-327. doi: 10.1002/npr2.12364. Epub 2023 Jul 18. Neuropsychopharmacol Rep. 2023. PMID: 37463744 Free PMC article. Review.
Most trials evaluated the efficacy of riluzole as an augmentation therapy with selective serotonin reuptake inhibitors and other antidepressants for PTSD, OCD, or GAD. ...CONCLUSIONS: This review found insufficient evidence to confirm the effects of riluzole for psy …
Most trials evaluated the efficacy of riluzole as an augmentation therapy with selective serotonin reuptake inhibitors and other anti …
Effects of Benzothiazolamines on Voltage-Gated Sodium Channels.
Farinato A, Altamura C, Desaphy JF. Farinato A, et al. Handb Exp Pharmacol. 2018;246:233-250. doi: 10.1007/164_2017_46. Handb Exp Pharmacol. 2018. PMID: 28939972 Review.
Riluzole is clinically used as a neuroprotectant in amyotrophic lateral sclerosis. Inhibition of Na(v) channels by riluzole is voltage-dependent due to preferential binding to inactivated sodium channels. ...
Riluzole is clinically used as a neuroprotectant in amyotrophic lateral sclerosis. Inhibition of Na(v) channels by riluzole is …
Treatment of hereditary amyotrophic lateral sclerosis.
Corcia P, Blasco H, Beltran S, Piegay AS, Vourc'h P. Corcia P, et al. Rev Neurol (Paris). 2023 Jan-Feb;179(1-2):54-60. doi: 10.1016/j.neurol.2022.09.001. Epub 2022 Nov 3. Rev Neurol (Paris). 2023. PMID: 36336493 Review.
Currently, only four molecules can be prescribed for amyotrophic lateral sclerosis (ALS), of which only one is approved worldwide for this indication, riluzole. Although progress in the therapeutic field remains unsatisfactory, we have to notice that genetics have undergon …
Currently, only four molecules can be prescribed for amyotrophic lateral sclerosis (ALS), of which only one is approved worldwide for this i …
2,018 results